Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma.

Gini G, Annibali O, Lupasco D, Bocci C, Tomarchio V, Sampaolo M, Trappolini S, Tafuri MA, Cacciagiù S, Ciccarone M, Barucca A, Sarlo C, Vincenzi B, Avvisati G, Leoni P, Olivieri A.

Chemotherapy. 2019;64(1):36-41. doi: 10.1159/000499535. Epub 2019 May 22.

2.

Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.

Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Semin Hematol. 2018 Oct;55(4):209-214. doi: 10.1053/j.seminhematol.2018.02.006. Epub 2018 Feb 21. Review.

PMID:
30502849
3.

Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients.

Annibali O, Piccioni L, Tomarchio V, Circhetta E, Sarlo C, Franceschini L, Cantonetti M, Rizzo E, Angeletti S, Tirindelli MC, Scagnolari C, Statzu M, Avvisati G, Riva E.

PLoS One. 2018 Jul 23;13(7):e0200221. doi: 10.1371/journal.pone.0200221. eCollection 2018.

4.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS).

Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. No abstract available.

PMID:
30029156
5.

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A.

Bone Marrow Transplant. 2017 Mar;52(3):473-475. doi: 10.1038/bmt.2016.308. Epub 2016 Dec 12. No abstract available.

PMID:
27941782
6.

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. eCollection 2016. Review.

7.

'Real Life' experience in a 'difficult to treat' patient population of non-Hodgkin lymphomas using the R-COMP regimen.

Annibali O, Chiodi F, Cenfra N, Sarlo C, Mega S, Cavallari I, Rago A, Tomassini S, Mecarocci S, Cimino G, Avvisati G.

Leuk Lymphoma. 2016 Dec;57(12):2919-2922. Epub 2016 Apr 11. No abstract available.

PMID:
27063923
8.

Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.

Annibali O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, Bianchi A, Bonini S, Avvisati G.

Biomed Res Int. 2015;2015:895105. doi: 10.1155/2015/895105. Epub 2015 Sep 6.

9.

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Ann Hematol. 2015 Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5. Epub 2015 Apr 14.

PMID:
25869029
10.

Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24.

11.

High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma.

Del Principe MI, Buccisano F, Cefalo M, Maurillo L, Di Caprio L, Di Piazza F, Sarlo C, De Angelis G, Irno Consalvo M, Fraboni D, De Santis G, Ditto C, Postorino M, Sconocchia G, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2014 Sep;93(9):1509-13. doi: 10.1007/s00277-014-2080-6. Epub 2014 Apr 22.

PMID:
24752416
12.

Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.

Del Principe MI, Cefalo M, Buccisano F, Anemona L, Sarlo C, Di Caprio L, De Santis G, Giacobbi E, Maurillo L, Postorino M, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2014 Sep;93(9):1611-2. doi: 10.1007/s00277-014-2010-7. Epub 2014 Jan 23. No abstract available.

PMID:
24452366
13.

Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.

Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di Veroli A, Nasso D, Ceresoli E, Postorino M, Di Piazza F, Colandrea G, Conti F, Del Poeta G, Amadori S, Venditti A.

Thromb Res. 2013 Nov;132(5):511-4. doi: 10.1016/j.thromres.2013.08.007. Epub 2013 Aug 16.

PMID:
24090605
14.

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2013 Jun 3;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013.

15.

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A.

Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28.

16.

Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes.

Buccisano F, Maurillo L, Neri B, Masala S, Mauriello A, Del Principe MI, Ditto C, Sarlo C, Cefalo M, Di Caprio L, Loreni G, Cicconi L, Amadori S, Venditti A.

J Clin Oncol. 2013 Apr 10;31(11):e189-91. doi: 10.1200/JCO.2012.45.3209. Epub 2013 Feb 19. No abstract available.

PMID:
23423741
17.

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.

Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo Coco F, Venditti A.

Blood. 2010 Sep 30;116(13):2295-303. doi: 10.1182/blood-2009-12-258178. Epub 2010 Jun 14.

18.

Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.

Ammatuna E, Sarlo C, Ottaviani L, Quaresima M, Buccisano F, Campagna S, Del Principe MI, De Angelis G, Anemona L, Gumenyuk S, Amadori S, Venditti A.

Leuk Lymphoma. 2009 May;50(5):857-8. doi: 10.1080/10428190902838392. No abstract available.

PMID:
19330655
19.

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A.

J Clin Oncol. 2008 Oct 20;26(30):4944-51. doi: 10.1200/JCO.2007.15.9814. Epub 2008 Jul 7.

PMID:
18606980
20.

Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.

Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A.

Eur J Haematol. 2008 Feb;80(2):107-14. Epub 2007 Nov 17.

PMID:
18028430
21.

Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.

Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, Del Principe MI, Mazzone C, Consalvo MI, Tamburini A, Ottaviani L, Fraboni D, Sarlo C, De Fabritiis P, Amadori S, Venditti A.

Haematologica. 2007 May;92(5):605-11.

22.

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.

Latagliata R, Breccia M, Carmosino I, Sarlo C, Montefusco E, Mancini M, Natalino F, Chistolini A, De Cuia R, Russo E, Morano GS, Biondo F, Spadea A, Mandelli F, Alimena G.

Leuk Res. 2005 Mar;29(3):287-91. Erratum in: Leuk Res. 2005 Sep;29(9):1099. Roberto, Latagliata [corrected to Latagliata, Roberto]; Massimo, Breccia [corrected to Breccia, Massimo]; Ida, Carmosino [corrected to Carmosino, Ida]; Chiara, Sarlo [corrected to Sarlo, Chiara]; Enrico, Montefusco [corrected to Montefusco, Enrico]; Marco,.

PMID:
15661264
23.

Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.

Breccia M, Mancini M, Nanni M, D'Elia GM, Carmosino I, Latagliata R, Sarlo C, Mandelli F, Alimena G.

Leuk Res. 2005 Jan;29(1):33-9.

PMID:
15541472

Supplemental Content

Support Center